The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

Fri, 03rd Feb 2023 15:17

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

4D Pharma PLC - Leeds-based pharmaceutical firm - Gives update on signal finding study of MRx0518 in combination with anti-PD-1 therapy Keytruda on patients with solid tumours that have progressed on a prior immune checkpoint inhibitor. In March, the company noted four patients with renal cell carcinoma, which had experienced durable stable disease. Renal cell carcinoma is a cancer of cells in the lining of tubules in the kidney. On Thursday, 4d Pharma says one of the four patients is partially responding to the treatment with MRx0518 in combination with anti-PD-1 therapy Keytruda. "Despite recent setbacks in the microbiome field experienced by other companies and the limitations on patient recruitment as a result of the administration, we are delighted that patients continue to benefit from the trial treatment. We continue to build on the body of evidence for the future development of MRx0518 and 4D's approach to Live Biotherapeutics," says Alex Stevenson, chief scientific officer at 4D pharma.

----------

Darktrace PLC - Cambridge, England-based cybersecurity business - Chief Executive Officer Poppy Gustafsson buys 48,000 shares for GBP2.254 each, worth GBP108,192.

----------

GCP Infrastructure Investments Ltd - Jersey, UK-based investment fund focused on UK infrastructure projects - Net asset value as at December 31 rises 6.0% to 113.59 pence per share from 107.18p a year prior. Says company was exposed to diversified and partially inflation protected portfolio with of 48 investments, up from 47 a year prior, with a valuation of GBP1.1 billion, unchanged. Like a year ago, the company's portfolio has a weight-adjusted average annualised yield of 7.9%. Says that it made five investments in the quarter to December 31, totalling GBP54.6 million, up from three investments totalling GBP52.8 million a year earlier.

----------

Greatland Gold PLC - London-headquartered mining development and exploration company, focused primarily on precious and base metal mining in Western Australia and Tasmania - Identifies bismuth in Western Australia at Juri joint venture, of which it owns 49% and Newcrest Mining Ltd 51%. Bismuth is a gold-copper mineralisation pathfinder element. Intersects 4 metres at 0.4 grams of gold per tonne at Black Hills hole, and 6 metres at 0.2 grams of gold per tonne at Black Hills hole. Notes that exploration confirms merit of follow-up drilling. Greatland Gold Managing Director Shaun Day says: "We are strongly encouraged by the results of our second drilling campaign at the Juri joint venture. The importance of bismuth as a pathfinder in the Paterson region is particularly significant with geochemistry at Black Hills similar to what we have seen at Havieron."

----------

Henderson Opportunities Trust PLC - Invests in the Asia Pacific region - Net asset value per share at October 31 falls 28% to 1,173.7p from 1,626.9p a year prior. NAV total return is negative 26%, including dividends reinvested, underperforming against its benchmark, which posts a negative return of 2.8%. Declares annual 34.0p per share dividend, up 24% from 27.5p a year prior. Looking ahead, says it is able to grow "substantially" despite a wider backdrop, with Chair Wendy Colquhoun noting that "this portfolio should not be seen as a proxy for the UK economy."

----------

Jadestone Energy PLC - Asia Pacific-focused oil and gas company - Says 2022 production averages 11,487 barrels of oil equivalent per day, down 8.4% from 12,545 a year ago. Company realises average oil price of USD103.93 per barrel in 2022, jumping 40% from USD74.34 a year ago. Revenue of about USD421 million is up 24% from USD340 million in 2021. Expects lifting of 4.0 million barrels of oil, down 13% from 4.6 million in 2021. Expects lifting of gas to triple in 2022 to 1.8 million cubic feet from 600,000 in 2021. In 2022, capital expenditure was about USD87 million, below the guidance of USD90 million to USD105 million but 55% higher than USD56.0 million in 2021. Looking into 2023, CEO Paul Blakeley says: "We are engaged in several mergers & acquisitions processes at present, and I am optimistic that we will be successful in resuming our growth trajectory in 2023, while remaining very disciplined about the opportunities we pursue."

----------

Mineral & Financial Investments Ltd - Cayman Island-based investor in the natural resources sector - Notes that Redcorp Empreedimentos Mineiros Lda finds 3.9% copper equivalent at Venda Nova South Zone in south Portugal. In addition, Mineral & Financial Chief Executive Officer Jacques Vaillancourt says: "We are encouraged by the confirmation that South Zone also appears to hold copper dominated mineralization similar to what we are seeing at depth in the North Zone. Additional drilling in the future is expected to expand on these discoveries."

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 Jan 2020 08:42

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

Read more
6 Nov 2019 11:00

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Read more
6 Nov 2019 09:36

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

Read more
5 Nov 2019 15:13

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

Read more
8 Oct 2019 10:35

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

Read more
8 Oct 2019 09:14

4d Pharma And Merck To Collaborate On Gut Disease Treatments

4d Pharma And Merck To Collaborate On Gut Disease Treatments

Read more
8 Oct 2019 08:30

4D Pharma inks research collaboration agreement with Merck & Co

(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.

Read more
30 Sep 2019 09:33

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

Read more
27 Aug 2019 16:45

4D Pharma Appoints Sangamo Therapeutics Boss Macrae To Board

(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.Macrae currently serves as president & of

Read more
25 Jul 2019 11:26

4d Pharma Picks New Candidate; Encouraging Data On Lead Biotherapeutic

(Alliance News) - 4d Pharma PLC on Thursday announced positive preclinical data on lead biotherapeutic candidate MRx0518 and the identification of a new candidate as well.The new candidate,

Read more
8 Jul 2019 09:29

4d Pharma Begins Live Biotherapeutics Asthma Programme

(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.The double-blind, placebo-controlled study will enrol 90

Read more
13 Jun 2019 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Friday 14 JuneMP Evans GroupSerabi GoldMonday 17 JuneChallenger 18

Read more
30 May 2019 14:26

DIRECTOR DEALINGS: 4d Pharma Chair Buys GBP15,000 In Shares

LONDON (Alliance News) - 4d Pharma PLC on Thursday said that Chair David Norwood acquired 15,000 shares in the company.On Wednesday, Norwood bought the shares at 100.00 pence each for a of

Read more
21 May 2019 11:27

4D Pharma losses widen as it spends cash on development activities

(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.

Read more
21 May 2019 10:29

4d Pharma Annual Loss Widens On Live Biotherapeutic Development Costs

LONDON (Alliance News) - 4d Pharma PLC on Tuesday said its loss widened in 2018 on research and development costs as it continued to develop its live biotherapeutic products, which contain living

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.